68 related articles for article (PubMed ID: 25477449)
1. Translational Medicine. A target for pharmacological intervention in an untreatable human disease.
Johnson SC
Science; 2014 Dec; 346(6214):1192. PubMed ID: 25477449
[No Abstract] [Full Text] [Related]
2. Medicine. A common pathway for a rare disease?
Vafai SB; Mootha VK
Science; 2013 Dec; 342(6165):1453-4. PubMed ID: 24357304
[No Abstract] [Full Text] [Related]
3. mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome.
Johnson SC; Yanos ME; Kayser EB; Quintana A; Sangesland M; Castanza A; Uhde L; Hui J; Wall VZ; Gagnidze A; Oh K; Wasko BM; Ramos FJ; Palmiter RD; Rabinovitch PS; Morgan PG; Sedensky MM; Kaeberlein M
Science; 2013 Dec; 342(6165):1524-8. PubMed ID: 24231806
[TBL] [Abstract][Full Text] [Related]
4. Neurometabolic disease: Treating mitochondrial diseases with mTOR inhibitors--a potential treatment for Leigh syndrome?
Geach T
Nat Rev Neurol; 2014 Jan; 10(1):2. PubMed ID: 24296657
[No Abstract] [Full Text] [Related]
5. Differential effects of mTOR inhibition and dietary ketosis in a mouse model of subacute necrotizing encephalomyelopathy.
Bornstein R; James K; Stokes J; Park KY; Kayser EB; Snell J; Bard A; Chen Y; Kalume F; Johnson SC
Neurobiol Dis; 2022 Feb; 163():105594. PubMed ID: 34933094
[TBL] [Abstract][Full Text] [Related]
6. The use of calorie restriction mimetics to study aging.
Kitada M; Koya D
Methods Mol Biol; 2013; 1048():95-107. PubMed ID: 23929100
[TBL] [Abstract][Full Text] [Related]
7. Targeting NAD
Lee CF; Caudal A; Abell L; Nagana Gowda GA; Tian R
Sci Rep; 2019 Feb; 9(1):3073. PubMed ID: 30816177
[TBL] [Abstract][Full Text] [Related]
8. PKC downregulation upon rapamycin treatment attenuates mitochondrial disease.
Martin-Perez M; Grillo AS; Ito TK; Valente AS; Han J; Entwisle SW; Huang HZ; Kim D; Yajima M; Kaeberlein M; Villén J
Nat Metab; 2020 Dec; 2(12):1472-1481. PubMed ID: 33324011
[TBL] [Abstract][Full Text] [Related]
9. Multimodal biomarker investigation on efficacy and mechanism of action for the mammalian target of rapamycin inhibitor, temsirolimus, in a preclinical mammary carcinoma OncoMouse model: a translational medicine study in support for early clinical development.
Wang X; Zhan Y; Zhao L; Alvarez J; Chaudhary I; Zhou BB; Abraham RT; Feuerstein GZ
J Pharmacol Exp Ther; 2011 Nov; 339(2):421-9. PubMed ID: 21835932
[TBL] [Abstract][Full Text] [Related]
10. Expression of budding yeast FKBP12 confers rapamycin susceptibility to the unicellular red alga Cyanidioschyzon merolae.
Imamura S; Ishiwata A; Watanabe S; Yoshikawa H; Tanaka K
Biochem Biophys Res Commun; 2013 Sep; 439(2):264-9. PubMed ID: 23973485
[TBL] [Abstract][Full Text] [Related]
11. Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment.
Ponticelli C; Locatelli F
Nephrol Dial Transplant; 2010 Dec; 25(12):3809-12. PubMed ID: 20798121
[No Abstract] [Full Text] [Related]
12. Calorie restriction and rapamycin inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity.
Nogueira LM; Dunlap SM; Ford NA; Hursting SD
Endocr Relat Cancer; 2012 Feb; 19(1):57-68. PubMed ID: 22143497
[TBL] [Abstract][Full Text] [Related]
13. Blocking the mTOR pathway: a drug discovery perspective.
Garcia-Echeverria C
Biochem Soc Trans; 2011 Apr; 39(2):451-5. PubMed ID: 21428918
[TBL] [Abstract][Full Text] [Related]
14. mTOR inhibitors in sarcoma.
Demetri GD
Clin Adv Hematol Oncol; 2011 Feb; 9(2):145-7. PubMed ID: 22379663
[No Abstract] [Full Text] [Related]
15. Everolimus limits aortic aneurysm in the apolipoprotein E-deficient mouse by downregulating C-C chemokine receptor 2 positive monocytes.
Moran CS; Jose RJ; Moxon JV; Roomberg A; Norman PE; Rush C; Körner H; Golledge J
Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):814-21. PubMed ID: 23393391
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats.
Renken C; Fischer DC; Kundt G; Gretz N; Haffner D
Nephrol Dial Transplant; 2011 Jan; 26(1):92-100. PubMed ID: 20615907
[TBL] [Abstract][Full Text] [Related]
17. mTOR inhibition and erythropoiesis: microcytosis or anaemia?
Diekmann F; Rovira J; Diaz-Ricart M; Arellano EM; Vodenik B; Jou JM; Vives-Corrons JL; Escolar G; Campistol JM
Nephrol Dial Transplant; 2012 Feb; 27(2):537-41. PubMed ID: 21785038
[TBL] [Abstract][Full Text] [Related]
18. [Role of mTOR inhibition in the treatment of metastatic renal cell carcinoma].
Mizuno R; Miyajima A; Oya M
Nihon Jinzo Gakkai Shi; 2012; 54(5):581-5. PubMed ID: 22991836
[No Abstract] [Full Text] [Related]
19. Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment.
Piha-Paul SA; Hong DS; Kurzrock R
J Clin Oncol; 2011 Apr; 29(12):e333-5. PubMed ID: 21263090
[No Abstract] [Full Text] [Related]
20. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
Wüthrich RP; Kistler AD; Serra AL
Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
